<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094821</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 276-05</org_study_id>
    <secondary_id>IND 68,208</secondary_id>
    <nct_id>NCT01094821</nct_id>
  </id_info>
  <brief_title>Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers</brief_title>
  <official_title>A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Effect of ATI-7505 on Gastric Emptying and Small Bowel and Colonic Transit in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARYx Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacodynamic study in healthy volunteers to determine the effects of a new 5-HT4&#xD;
      agonist on gastric, small bowel and colonic transit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ATI-7505, is an engineered analog of the 5-HT4 agent, cisapride. The objectives of this study&#xD;
      are to compare effects of ATI-7505 and placebo on gastric, small bowel and colonic transit in&#xD;
      healthy human volunteers and evaluate the safety and tolerability of ATI-7505.&#xD;
&#xD;
      This trial is a double-blind, randomized, placebo-controlled study evaluating the&#xD;
      gastrointestinal transit effects of ATI-7505 and placebo. Three different doses (3, 10, 30mg)&#xD;
      of ATI-7505 and placebo will be administered in parallel to four independent groups of 12&#xD;
      subjects each. The maximum duration of drug exposure for any subject is 9 days.&#xD;
&#xD;
      All participants will undergo a standard 48 hour gastrointestinal transit measurement using&#xD;
      scintigraphy with standardized meals during the first 12 hours. The response endpoints&#xD;
      (colonic geometric center at 4 h, colonic geometric center at 24 h, colonic geometric center&#xD;
      at 48 h, gastric residual at 2 &amp; 4 h, colonic filling at 6 h and ascending colonic emptying&#xD;
      t1/2) will be based on abdominal scintigraphic images following the technetium-99m egg meal&#xD;
      and methacrylate-coated, delayed-release capsule containing 111In labeled activated charcoal.&#xD;
&#xD;
      Safety and tolerability will be evaluated by serial assessment of vital signs, physical&#xD;
      examination, ECG, adverse events, concomitant medications and blood sample analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic geometric center at 24 h</measure>
    <time_frame>24 hours</time_frame>
    <description>Colonic geometric center determined 24 hours post first camera image following ingestion of study medication with Indium-111 capsule and breakfast with Technetium-99 labeled egg breakfast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ascending colonic emptying t1/2</measure>
    <time_frame>24 hours</time_frame>
    <description>As measured with scintigraphic method following 111In labeled capsule and 99Tc labeled egg breakfast</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric emptying of solids (T1/2)</measure>
    <time_frame>4 hours</time_frame>
    <description>As measured with scintigraphic method following technetium-99m egg meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colonic filling at 6 h</measure>
    <time_frame>6 hours</time_frame>
    <description>As measured with scintigraphic method following ingestion of 111In labeled capsule and 99Tc labeled egg breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic geometric center at 48 hours</measure>
    <time_frame>48 hours</time_frame>
    <description>As measured with scintigraphic method following ingestion of In111 capsule and Tc99 labeled breakfast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent gastric emptying at 1, 2 and 4 hours</measure>
    <time_frame>4 hours</time_frame>
    <description>As measured with scintigraphic method following ingestion of 99Tc labeled egg breakfast</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>3 mg ATI-7505</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule three times daily for 9 days followed by transit scintigraphy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg ATI-7505</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg ATI-7505</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATI-7505</intervention_name>
    <description>3 mg three times daily for 9 days</description>
    <arm_group_label>3 mg ATI-7505</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule three times daily for 9 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATI-7505</intervention_name>
    <description>10 mg ATI-7505 three times daily for 9 days</description>
    <arm_group_label>10 mg ATI-7505</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATI-7505</intervention_name>
    <description>20 mg ATI-7505 three times daily for 9 days</description>
    <arm_group_label>20 mg ATI-7505</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers between the ages of 18 to 65 years old (inclusive) with a BMI&#xD;
             &amp;#8805; 18 and &amp;#8804; 32&#xD;
&#xD;
          2. PR, QRS and QT intervals within normal limits on screening ECG. Specifically, PR &lt; 220&#xD;
             msec, QRS &lt; 140 msec, QTc &lt; 450 msec&#xD;
&#xD;
          3. Are able and willing to understand study requirements, follow instructions, attend all&#xD;
             required study visits (especially during 48 hrs of scintigraphic scan), undergo all&#xD;
             planned tests (including drawing of blood samples and consumption of standardized&#xD;
             study meals)&#xD;
&#xD;
          4. Are able and willing to sign IRB-approved, written informed consent to participate in&#xD;
             this study&#xD;
&#xD;
          5. Have had negative urine screen and clinical history (prior 2 years) for drugs of abuse&#xD;
             at screening visit&#xD;
&#xD;
          6. Women with no child bearing potential, as defined by at least 1 year post-menopausal&#xD;
             (absence of vaginal bleeding or spotting) or surgically sterile. Men will have a&#xD;
             sterile sexual partner or will, starting at time of study drug administration a&#xD;
             minimum of 1 month after study drug administration, be willing to use an approved&#xD;
             method of contraception (which may include use of a condom with spermicide or use by&#xD;
             partner of oral, implantable or injectable contraceptives, IUD, diaphragm with&#xD;
             spermicide)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Inability to understand study requirements or follow study procedures (especially&#xD;
             entire 48 h of scintigraphy examination), attend all required study visits, undergo&#xD;
             all planned tests (including drawing of blood samples and consumption of study meals)&#xD;
&#xD;
          2. Any out of range laboratory value at screening that has not been reviewed, approved&#xD;
             and documented as not clinically significant (NCS) by the Principal Investigator.&#xD;
&#xD;
          3. Use of alcohol within 24 h of randomization visit (Visit 2) and through completion of&#xD;
             the study&#xD;
&#xD;
          4. History of untoward effects of metoclopramide&#xD;
&#xD;
          5. Any clinically significant abnormality on screening ECG.&#xD;
&#xD;
          6. Any other condition or clinically significant abnormal findings on the physical&#xD;
             examination, medical history, or clinical laboratory results during screening that, in&#xD;
             the opinion of the Principal Investigator, would make the subject unsuitable for the&#xD;
             study or put them at additional risk)&#xD;
&#xD;
          7. Known allergy, hypersensitivity or sensitivity to cisapride&#xD;
&#xD;
          8. Pregnancy or lactation&#xD;
&#xD;
          9. History of alcohol or other substance abuse within the past two years&#xD;
&#xD;
         10. Received treatment with any other investigational drug within the preceding 30 days or&#xD;
             5 half-lives, whichever is greater&#xD;
&#xD;
         11. Major surgery within 3 months of study entry and any surgery within 2 weeks of study&#xD;
             entry unless approved by the Principal Investigator and Sponsor?s Medical Monitor&#xD;
&#xD;
         12. Any documented history of irregular intestinal transit including but not limited to&#xD;
             gastro-esophageal reflux disease (GERD), gastroparesis of any kind, irritable bowel&#xD;
             syndrome, inflammatory bowel disease and chronic constipation or diarrhea under the&#xD;
             care of a physician and/or requiring daily medication&#xD;
&#xD;
         13. Any history of gastrointestinal tract or abdominal surgery, except tubal ligation,&#xD;
             hysterectomy, appendectomy, cholecystectomy or hemorrhoid surgery &gt; 3 months prior to&#xD;
             screening&#xD;
&#xD;
         14. More than three positive (i.e., ?yes?) responses on screening bowel symptom&#xD;
             questionnaire&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Camilleri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Camilleri M, Vazquez-Roque MI, Burton D, Ford T, McKinzie S, Zinsmeister AR, Druzgala P. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil. 2007 Jan;19(1):30-8.</citation>
    <PMID>17187586</PMID>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <last_update_submitted>March 26, 2010</last_update_submitted>
  <last_update_submitted_qc>March 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Michael Camilleri</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>ATI-7505</keyword>
  <keyword>Scintigraphy</keyword>
  <keyword>Gastrointestinal transit</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ATI 7505</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

